Health
Newer Type 2 diabetes medications could reduce kidney, heart disease risks – News-Medical.Net
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Reviewed by Emily Henderson, B.Sc.Sep 28 2020
Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.
Based on analyses of the clinical trials through March 2020, a group of leading experts in diabetes, heart failure, kidney disease and cardiometabolic disease believe the medicines should be considered for people with CKD and…
-
Noosa News19 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
General24 hours agoIranian supreme leader makes first public appearance since war with Israel
-
Noosa News24 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
Noosa News18 hours agoMissing man, Maroochydore – Queensland Police News